Alcohol

Alcohol

SCHEMBL3199084

CCO.C[C@@H]1CCC[C@@]2(C)CC[C@H]3[C@H](C)CC[C@@H](C[C@H]12)C3(C)C

nearest known ligand 0.39

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Alcohol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
NR1I3 Q14994 1/20 0.39
CDK5 Q00535 1/20 0.36
CDK5R1 Q15078 1/20 0.36
GRIN1 Q05586 4/20 0.34
GRIN2B Q13224 4/20 0.34
AKR1B10 O60218 1/20 0.34
RET P07949 1/20 0.33
MAPK14 Q16539 1/20 0.33
CAMK1D Q8IU85 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901326 0.92 CDK5 (0.40) NR1I3CDK5CDK5R1GRIN1GRIN2B
SCHEMBL332530 0.92 CDK5 (0.40) NR1I3CDK5CDK5R1GRIN1GRIN2B
SCHEMBL3825 0.92 CDK5 (0.40) NR1I3CDK5CDK5R1GRIN1GRIN2B
Water SCHEMBL3935755 0.91 CDK5 (0.39) NR1I3CDK5CDK5R1GRIN1GRIN2B
SCHEMBL789094 0.91 CDK5 (0.39) NR1I3CDK5CDK5R1GRIN1GRIN2B
Water SCHEMBL1070875 0.91 CDK5 (0.39) NR1I3CDK5CDK5R1GRIN1GRIN2B
Water SCHEMBL1888091 0.91 CDK5 (0.39) NR1I3CDK5CDK5R1GRIN1GRIN2B
Ammonia Solution, Strong SCHEMBL2074263 0.91 CDK5 (0.39) NR1I3CDK5CDK5R1GRIN1GRIN2B
SCHEMBL17856475 0.90 NR1I3 (0.40) NR1I3CDK5CDK5R1GRIN1GRIN2B
Ether SCHEMBL2165966 0.89 CDK5 (0.35) NR1I3CDK5CDK5R1GRIN1GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101648973-A Water-soluble taxane and preparation method thereof YOUMAO QI 2010-02-17 CN claimed
EP-1370541-B1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID DABUR INDIA LTD (IN) 2006-11-02 EP claimed
EP-1370541-A1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID Dabur India Limited (IN) 2003-12-17 EP claimed
US-20030013888-A1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID DABUR PHARMA LIMITED (IN) 2003-01-16 US claimed
US-6506905-B1 Taxol intermediates DABUR INDIA LIMITED (IN) 2003-01-14 US claimed
WO-2002066448-A1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID DABUR INDIA LIMITED (IN) 2002-08-29 WO claimed
CN-117999304-A Hydrophobic drug polymer micelle and preparation method thereof 南京再明医药有限公司 2024-05-07 CN disclosed
CN-104822262-A Non-aqueous taxane nanodispersion formulations and methods of use thereof TEIKOKU PHARMA USA INC 2015-08-05 CN disclosed
CN-101648973-B Water-soluble taxane and preparation method thereof YOUMAO QI 2012-05-30 CN disclosed
CN-101648973-A Water-soluble taxane and preparation method thereof YOUMAO QI 2010-02-17 CN disclosed
US-20100035977-A1 TWO-COMPONENT TAXANE CONTAINING PHARMACEUTICAL COMPOSITION KYSILKA VLADIMIR 2010-02-11 US disclosed
EP-2124929-A1 A TWO-COMPONENT TAXANE CONTAINING PHARMACEUTICAL COMPOSITION Heaton A.S. (CZ) 2009-12-02 EP disclosed
CN-100483128-C Solid phase extraction kit filled with HP20 resin and methods employed of the same UNIV SHANGHAI JIAOTONG (CN) 2009-04-29 CN disclosed
US-6506905-B1 Taxol intermediates DABUR INDIA LIMITED (IN) 2003-01-14 US disclosed
US-20020168745-A1 Protein for use in the generation of taxol and taxoids for use in the treatment of cancer WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2002-11-14 US disclosed
US-20020138859-A1 Transacylases of the paclitaxel biosynthetic pathway WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2002-09-26 US disclosed
WO-2002066448-A1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID DABUR INDIA LIMITED (IN) 2002-08-29 WO disclosed
EP-1220930-A2 TRANSACYLASES OF THE PACLITAXEL BIOSYNTHETIC PATHWAY WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2002-07-10 EP disclosed
US-6287835-B1 MOLECULAR HYBRIDIZATION; GENE EXPRESSION, GENETIC ENGINEERING WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION 2001-09-11 US disclosed
WO-2001023586-A2 TRANSACYLASES OF THE PACLITAXEL BIOSYNTHETIC PATHWAY WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013888-A1 METHOD OF PREPARATION OF PACLITAXEL (TAXOL) USING 3-(ALK-2-YNYLOXY) CARBONYL-5-OXAZOLIDINE CARBOXYLIC ACID ALK, AHR, PDGFRA NR1I3 1164/4885CDK5 1265/4885CDK5R1 2017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.